IceCure Medical is a commercial stage medical device company focusing on the research, development and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation is the process by which benign and malignant tumors are ablated (destroyed) through freezing while in a patient's body. Co.'s proprietary cryoablation technology is for surgical intervention such as tumors, including those found in breast, lungs, kidneys, bones and other indications. Co.'s commercial cryoablation product is the ProSense system. Co. has developed an additional multi probe system, which it refers to as its MultiSense system. The ICCM stock yearly return is shown above.
The yearly return on the ICCM stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ICCM annual return calculation with any dividends reinvested as applicable (on ex-dates).
|